Fig. 6: Therapy-related clonal cytopenia (t-CC) is a distinct clinical entity characterized by superior survival compared to therapy-related myeloid neoplams (t-MN).
From: Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
(i) Overall survival (OS) in therapy-related clonal cytopenia (t-CC) as stratified by the subsequent development of therapy-related myeloid neoplasm (t-MN); (ii) t-CC has significantly superior OS compared to t-MN, including compared to t-MDS (<5% bone marrow blasts). t-MDS (cyto)—therapy-related myelodysplastic syndrome based on the presence of MDS-defining cytogenetics; t-MDS (<5%)—t-MDS with <5% blasts at the time of presentation; t-MDS (EB)—t-MDS with excess blasts (5–19%); t-AML—therapy-related acute myeloid leukemia.
